David N Lieberman MD PhD
Assistant in Neurology, Boston Children's Hospital
Join to view full profile
300 Longwood AvenueDepartment of Neurology Fegan 11Boston, MA 02115
Phone+1 617-355-2063
Fax+1 617-730-0288
Dr. Lieberman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- David Lieberman, MD, is a child neurologist based in Boston, MA, with his educational background comprising a fellowship in Child Neurology and a transitional year internship at Johns Hopkins University, following his graduation from Stanford University School of Medicine in 2000. He is currently a Clinical Instructor at Boston Children's Hospital, a position he has held since 2015. Dr. Lieberman has authored several publications focusing on Rett syndrome and related neurodevelopmental disorders, which have been featured in reputable journals such as the Journal of Neurodevelopmental Disorders, Genes, and the Annals of Neurology. His research includes investigations into ketamine's effects in Rett syndrome and has been cited in the academic field.
Education & Training
Johns Hopkins UniversityFellowship, Child Neurology, 2001 - 2004- Johns Hopkins University School of MedicineInternship, Transitional Year, 2000 - 2001
Stanford University School of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2021 - Present
MA State Medical License 2015 - 2027
NH State Medical License 2024 - 2024
CA State Medical License 2007 - 2021
ME State Medical License 2020 - 2021
MD State Medical License 2006 - 2008
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Publications & Presentations
PubMed
- Speech, language, social communication, and communication assessments in Rett syndrome: A systematic review.Lucas N Raniolo, Ruth O Braden, Jana von Hehn, John Christodoulou, David N Lieberman
Developmental Medicine and Child Neurology. 2026-08-10 - 9 citationsResults from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome.Alan K Percy, Robin Ryther, Eric D Marsh, Jeffrey L Neul, Timothy A Benke
Med. 2025-06-13 - 5 citationsA randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome.Kathleen Campbell, Jeffrey L Neul, David N Lieberman, Elizabeth Berry-Kravis, Tim A Benke
Journal of Neurodevelopmental Disorders. 2025-01-24
Press Mentions
- FDA Approval of Trofinetide May Spur Further Drug Development for Rett | SpectrumMarch 17th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: